Every Form 4 that Apnimed, Inc. (APMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow APMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APMD filings page.
Morningside Venture Investments Ltd, a 10% owner of Apnimed, Inc., reported IPO-related restructuring transactions and a share purchase. Convertible preferred stock automatically converted into 6,840,213 shares of Class A Common Stock immediately prior to the IPO closing, then Class A was reclassified into common stock in a transaction described as exempt under Rule 16b-7. A $1,000,000 convertible promissory note, bearing 8% then 15% interest, automatically converted into 75,624 Class A shares at a $14.40 conversion price based on an IPO price of $16 per share. In addition, the reporting person purchased 312,500 shares of common stock at $16 per share in an open-market or private transaction. Certain shares are held indirectly through MVIL, LLC, and Morningside’s directors share voting and dispositive power and disclaim beneficial ownership.
Apnimed, Inc. reported that investment entities associated with Alpha Wave Ventures and related parties converted several derivative securities into Common Stock in connection with the closing of its IPO. Series C-1, C-2 and C-3 Preferred Stock automatically converted into an aggregate of 5,540,476 shares of Common Stock, and Convertible Notes converted into 1,512,480 shares of Common Stock at a $14.40 per-share conversion price. Footnotes state these preferred shares converted on a 0.741-for-one basis into Class A Common Stock immediately prior to a reclassification into Common Stock exempt under Rule 16b-7, and that the Convertible Promissory Note’s $20,000,000 principal plus $1,779,726 accrued interest automatically converted before its September 17, 2027 maturity date. The reporting persons expressly disclaim beneficial ownership except to the extent of any pecuniary interest.
Apnimed, Inc. director and Chief Executive Officer Kevin Robert Lind reported several derivative transactions in stock options on Class A Common Stock and Common Stock. On 2026-08-03, existing options tied to Class A Common Stock were disposed of to the issuer and corresponding options on Common Stock were acquired in equal amounts, reflecting a reclassification exempt under Rule 16b-7 and Rule 16b-3. The affected grants cover 74,128 options at an exercise price of $9.50 expiring 2035-03-06, and blocks of 1,186,278 and 108,916 options at exercise prices of $8.15 and $16.00, both expiring 2036-06-23 and 2036-07-29, respectively. Footnotes describe time-based vesting over four years, contingent on Lind’s continuous service to Apnimed.
Apnimed, Inc. reported equity award changes for Chief Financial Officer Michael B. Kelly. Existing stock options for 333,580 shares at an exercise price of $8.15 and separate options for 31,434 shares at $16.00 were reclassified from Class A Common Stock into Common Stock pursuant to exemptions under Rule 16b-7 and Rule 16b-3, resulting in offsetting dispositions to and grants from the issuer with no net change in option count. These options expire in 2036 and vest 25% after twelve months from June 22, 2026, with the remainder vesting in substantially equal monthly installments over the following 36 months, subject to continued service.
Apnimed, Inc. director Paul R. Fonteyne reported multiple option transactions involving the company’s equity awards. On 2026-08-03, he disposed of and simultaneously acquired stock options covering 51,890 shares at a $4.00 exercise price and separate options covering 44,477 shares at $8.15 and $16.00 per share, in each case linked to a reclassification in which each share of Common Stock was reclassified into one share of Series A Common Stock, exempt under Rule 16b-7 and Rule 16b-3. A prior grant on 2026-07-30 for options on 44,477 shares at a $16.00 exercise price is also reported. The footnotes describe time-based vesting schedules over 36–48 months, conditioned on Fonteyne’s continuous service to Apnimed.
Apnimed, Inc. director Gary Sender reported several stock option movements involving Class A Common Stock and Common Stock. On August 3, 2026, options over 51,890 shares at a $9.50 exercise price, 44,477 shares at $8.15, and 44,477 shares at $16.00 were recorded as dispositions to the issuer and corresponding acquisitions, reflecting a reclassification of Class A Common Stock into Common Stock pursuant to Rules 16b-7 and 16b-3. Separately, on July 30, 2026, Sender received a new option grant for 44,477 shares at $16.00, vesting in substantially equal monthly installments over 36 months after July 30, 2026.
Apnimed, Inc. director Paul J. Sekhri reported several equity awards and a share purchase. On 2026-08-03, he reported paired dispositions to the issuer and grants of stock options over 169,468 shares at an exercise price of $8.15 per share and options over 177,796 shares at $16.00 per share, reflecting a reclassification in which each share of Class A Common Stock became one share of Common Stock. The options vest over multi-year schedules beginning in 2026. He also purchased 12,500 shares of Common Stock at $16.00 per share on 2026-08-03, held directly.
Apnimed, Inc. director William A. Jones Jr. reported derivative transactions involving stock options for 44,477 shares of common stock at an exercise price of $16.00 per share, expiring on July 29, 2036. The options are scheduled to vest in substantially equal monthly installments over 36 months after July 30, 2026, contingent on his continued service. The filing also notes a reclassification in which each share of Class A common stock was reclassified into one share of common stock pursuant to Rule 16b-7 and Rule 16b-3, which is described as an exempt reclassification.
Apnimed, Inc. director Lawrence G. Miller reported a series of equity reclassification and option-related transactions dated August 3, 2026. A key step was the conversion of 10,845 shares of Series A Preferred Stock into an equal number of shares of Class A Common Stock, then into Common Stock, in connection with the issuer’s initial public offering and a one-for-one reclassification of Class A Common Stock into Common Stock pursuant to Rule 16b-7 and Rule 16b-3.
Miller also reported multiple paired transactions in which stock options and shares labeled as Class A Common Stock (and trust-held Class A Common Stock) were disposed of and corresponding options or shares labeled as Common Stock were acquired in identical amounts, at exercise prices ranging from $1.00 to $8.88 per share, with various vesting schedules. Footnotes state that 100% of the shares subject to certain options are fully vested, and others vest over 24–48 months of continuous service. Several positions are held indirectly through irrevocable family trusts, and Miller disclaims beneficial ownership except to the extent of any pecuniary interest.
Apnimed, Inc. President Dennis Patrick Molnar reported a series of internal equity adjustments and option grants. On 2026-08-03, each share of Class A Common Stock was reclassified into one share of Common Stock under Rule 16b-7 and Rule 16b-3, resulting in paired dispositions and acquisitions of both common shares and multiple stock option awards at exercise prices ranging from $1.00 to $16.00 per share. A separate stock option for 55,596 shares at $16.00 per share was granted on 2026-07-30, vesting in substantially equal monthly installments over 24 months after July 30, 2026.